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Abstract
Background: Observational studies investigating risk factors in coronavirus disease 2019 (COVID-19) have not
considered the confounding effects of advanced care planning, such that a valid picture of risk for elderly, frail and
multi-morbid patients is unknown. We aimed to report ceiling of care and cardiopulmonary resuscitation (CPR)
decisions and their association with demographic and clinical characteristics as well as outcomes during the COVID-
19 pandemic.
Methods: Retrospective, observational study conducted between 5th March and 7th May 2020 of all hospitalised
patients with COVID-19. Ceiling of care and CPR decisions were documented using the Recommended Summary
Plan for Emergency Care and Treatment (ReSPECT) process. Unadjusted and multivariable regression analyses were
used to determine factors associated with ceiling of care decisions and death during hospitalisation.
Results: A total of 485 patients were included, of whom 409 (84·3%) had a documented ceiling of care; level one
for 208 (50·9%), level two for 75 (18·3%) and level three for 126 (30·8%). CPR decisions were documented for 451
(93·0%) of whom 336 (74·5%) were ‘not for resuscitation’. Advanced age, frailty, White-European ethnicity, a
diagnosis of any co-morbidity and receipt of cardiovascular medications were associated with ceiling of care
decisions. In a multivariable model only advanced age (odds 0·89, 0·86–0·93 p < 0·001), frailty (odds 0·48, 0·38–0·60,
p < 0·001) and the cumulative number of co-morbidities (odds 0·72, 0·52–1·0, p = 0·048) were independently
associated. Death during hospitalisation was independently associated with age, frailty and requirement for level
two or three care.
Conclusion: Ceiling of care decisions were made for the majority of patients during the COVID-19 pandemic,
broadly in line with known predictors of poor outcomes in COVID-19, but with a focus on co-morbidities
suggesting ICU admission might not be a reliable end-point for observational studies where advanced care
planning is routine.
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Background
In December 2019, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first identified as the
causative agent for a cluster of pneumonia cases in Wu-
han City, China [1]. A global pandemic was declared by
the World Health Organisation (WHO) in March 2020,
which continues to challenge healthcare systems
globally. SARS-CoV-2 can result in a spectrum of illness,
from asymptomatic infection to coronavirus disease
2019 (COVID-19), a viral pneumonia resulting in high
rates of hospitalisation, intensive care unit (ICU) admis-
sion and requirement for mechanical ventilation [2, 3].
There has been considerable interest in exploring risk
factors for susceptibility to infection and severe disease
in COVID-19, with proposed risk factors including age
[4], cardiovascular co-morbidities (including diabetes
mellitus) [5], medications inhibiting the renin-
angiotensin-aldosterone system (RAAS) [6], obesity [7]
and ethnicity [8].
Observational data have resulted in contradictory find-
ings, possibly owing to heterogeneous definitions of
what constitutes severe disease, with hospitalisation, ICU
admission [3, 9, 10], mechanical ventilation [11] or death
[12, 13] explored as primary end-points. Despite this, lit-
tle is known about how decisions to limit care below full
intensive care-based treatments were made during the
COVID-19 pandemic.
The aims of this analysis were therefore firstly, to re-
port pre-emptive ceiling of care and cardiopulmonary
resuscitation (CPR) decisions in patients admitted with
SARS-CoV-2 infection in a large university teaching hos-
pital trust in the UK during the COVID-19 pandemic.
Secondly, we aimed to describe the demographic and
clinical characteristics associated with ceiling of care de-
cisions, along with reporting their clinical outcomes.
Methods
Patients
We performed a retrospective, observational study to ex-
plore factors associated with outcomes in COVID-19 at
the Leeds Teaching Hospitals NHS Trust (LTHT), one
of the largest university teaching hospitals in Europe,
comprising of two large and four smaller facilities pro-
viding over 1800 inpatient beds, serving a secondary care
population of more than 750,000 people. All patients
aged ≥18 years with laboratory confirmed SARS-CoV-2
infection hospitalised at LTHT between 5th March and
7th May 2020 were included. Approval was given follow-
ing institutional governance review and, in view of the
retrospective nature, individual patient consent was
waived as appropriate data protection safeguards were in
place. In keeping with WHO guidance, laboratory con-
firmation for SARS-CoV-2 was defined as a positive re-
sult of real-time reverse transcriptome-polymerase chain
reaction assay of nasal or pharyngeal swabs, or lower re-
spiratory tract aspirates [14]. Patients who tested posi-
tive, but admitted for other reasons or were infected
with SARS-CoV-2 during hospitalisation were excluded,
as were those who were assessed in the Emergency De-
partment but not hospitalised.
Data sources and definitions
Clinical data and outcomes were obtained from the
Leeds Patient Pathway Manager Plus electronic care rec-
ord, which updates mortality events daily directly from
the UK Office of National Statistics database. Ceiling of
care and CPR decisions were standardised and docu-
mented electronically using the Recommended Summary
Plan for Emergency Care and Treatment (ReSPECT)
process (Resuscitation Council UK) [15]. Demographic
data include age, sex and ethnicity. Ethnicity was self-
reported and classified according to the 2011 Census for
England, Northern Ireland and Wales as White-
European, South-Asian, East-Asian, Black-African,
mixed race and other ethnicities, and, for the purpose of
analysis, was dichotomised as White-European or Black,
Asian and minority ethnic (BAME). Clinical data include
major co-morbidities, frailty and the prescription of
medical therapy. Major co-morbidities were any of:
hypertension, diabetes mellitus, chronic kidney disease
(CKD) stage III-V, atrial fibrillation, chronic obstructive
pulmonary disease (COPD), ischaemic heart disease
(IHD), heart failure with reduced ejection fraction
(HFrEF), history of stroke or transient ischaemic attack
(TIA) and active malignancy. Frailty was classified by the
Canadian Study of Health and Aging Clinical Frailty
Scale (CFS) [16] according to national recommendations
[17], which, during the COVID-19 pandemic, was
mandatory for all patients assessed in the Emergency
Department at LTHT. Pre-admission medical therapy
was obtained by regular prescription information from
electronic primary care records. We recorded the pre-
scription of RAAS inhibitors, beta-blockers, calcium
channel blockers, diuretics, statins, antiplatelet and anti-
coagulants, medications for diabetes mellitus and im-
munosuppression. We recorded clinical markers of
disease severity at the time of hospitalisation, including
laboratory investigations, chest radiography and clinical
observations. Laboratory investigations included full
blood count, renal function and blood tests to stratify
disease severity, which were C-reactive protein, ferritin,
D-dimer and procalcitonin. All chest radiographs were
interpreted by a radiologist and graded as either being
consistent with, indeterminant for, or inconsistent with
COVID-19 pneumonia. Clinical observations included
heart rate, blood pressure, tympanic temperature, per-
ipheral oxygen saturations and respiratory rate, and were
obtained from the earliest assessment of physiology,
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usually recorded by paramedic crew or on arrival in the
Emergency Department.
Assessment of outcomes
Patients were followed-up until discharge from hospital
or death. Outcomes data include treatments adminis-
tered during hospitalisation, maximum level of care re-
ceived, and death prior to discharge. Administered
treatments were oxygen therapy, continuous positive
pressure ventilation (CPAP), mechanical ventilation, cir-
culatory support (vasopressors or inotropes) or new re-
quirement for renal replacement therapy. Level one care
was hospitalisation without need for organ support (but
including oxygen therapy) and delivered in a ward set-
ting; level two care was single organ support (usually
CPAP), but excluding mechanical ventilation, and deliv-
ered in either in a ward, high-dependency unit or ICU
setting; level three care was multi-organ support or
mechanical ventilation and delivered on the ICU.
Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics version 26 (IBM Corporation, Armonk, NY).
After testing for normality of distribution, continuous
variables are expressed as mean ± standard deviation or
median (interquartile range), as appropriate. Discrete
variables are presented as number (percentage), and or-
dinal data as median (interquartile range). Groups were
compared using Student’s t-test or one-way analysis of
variance for normally distributed continuous data, by
Mann-Whitney U test or Kruskal-Wallis H-test for non-
normally distributed continuous data and by Pearson χ2
tests for categorical data. Age-sex adjusted and multivar-
iable analyses were performed using binary logistic re-
gression analysis. All tests were two-sided and statistical
significance was defined as p < 0·05.
Results
Patients
Between 5th March and 7th May 2020, a total of 599 pa-
tients tested positive for SARS-CoV-2 in LTHT and of
these, 65 were admitted for reasons other than COVID-
19, 38 were not hospitalised, five were aged < 18 years
and six tests were subsequently amended as negative fol-
lowing quality control. The final dataset therefore con-
sisted of 485 patients, with a mean age of 71.2 ± 16.9
years of whom 259 (53·4%) were male. A total of 109
(22·5%), 130 (26·8%), 105 (21·6%) and 141 (29·1%) had
zero, one, two and three or more major co-morbidities,
respectively. The most common co-morbidity was
hypertension, which was present in 222 (45·8%) patients,
whilst 147 (30·3%) had diabetes mellitus (Table 1). Self-
reported ethnicity was available for 475 patients (97·9%),
of whom 402 (84·6%) classified themselves as White-
European, 31 (6·5) as South-Asian, 19 (4·0%) as Black-
African, two (0·4%) as East-Asian and 21 (4·4%) as either
mixed or other ethnicities.
Ceiling of care and cardiopulmonary resuscitation
decisions
Bar charts showing ceiling of care decisions divided by
patient demographics are displayed in Fig. 1. Following
consultation with patients, their next-of-kin and surro-
gate decision makers, pre-emptive ceiling of care deci-
sions were documented for 409 (84·3%) patients
hospitalised with SARS-CoV-2 infection. Of patients in
whom these decisions were made, 208 (50·9%), 75
(18·3%) and 126 (30·8%) patients were deemed suitable
for a maximum of level one, two or three care, respect-
ively. CPR decisions were made for 451 (93·0%) patients,
of whom 336 (74·5%) were deemed not for CPR in event
of cardiac arrest, with CPR deemed appropriate in 115
(25·5%).
Demographics and clinical characteristics
Patients considered suitable for escalation of treatment
were younger, less frail and had fewer major co-
morbidities. In unadjusted analysis, age was strongly
associated with treatment escalation decisions, most
evident in patients over 85 years of age (odds ratio (OR)
0·004, 95% confidence interval (CI) 0·001–0.017, p <
0·001). Other variables associated with ceiling of care de-
cisions were higher CFS, lower BMI, a diagnosis of any
major co-morbidity, the prescription of cardiovascular
medications and White-European ethnicity (Fig. 2).
Compared to White-European patients, BAME pa-
tients were on average younger (58·0 ± 15·4 vs 73·7 ±
16.0 years, p < 0·001), had fewer major co-morbidities (1
(0,2) vs 2 (1, 3), p = 0·037) and were less frail (CFS 2 (2,
4) vs 5 (3, 7), p < 0·001). When adjusted for age and sex,
ethnicity was not associated with ceiling of care deci-
sions, nor were there associations between ceiling of care
decisions and lower BMI or the prescription of most car-
diovascular medications. Associations between a ceiling
of care decision of less than level three and frailty, a
diagnosis of diabetes mellitus, COPD, CKD, history of
stroke or TIA and prescription of loop diuretic or statin
remained when adjusted for age and sex. In multivari-
able regression analysis, predictors of ceiling of care
decisions were advanced age (OR 1·1 per year, 95% CI
1·1–1·2, p < 0·001) and higher CFS (OR 2·1, 95% CI 1·7–
2·7, p < 0·001) (Table 2). No other clinical or demo-
graphic variables were independently associated with the
decision to limit the maximal care level provided. No in-
dividual co-morbidities featured as part of a multivari-
able analysis although there was a significant association
between the cumulative number of major co-morbidities
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and ceiling of care decisions (OR 1·4 per co-morbidity,
95% CI 1·0–1·9, p = 0·048) (Table 3).
Clinical markers of disease severity
Patients deemed inappropriate for level three care had
on average fewer markers of severe SARS-CoV-2 infec-
tion at the time of presentation compared to those who
were (Table 4). Laboratory markers of systemic inflam-
mation such as C-reactive protein and serum ferritin
were more often abnormal in patients deemed eligible
for escalation to level three care, as were assessments of
physiology such as respiratory rate, heart rate and tym-
panic temperature. Chest radiography data were
available for 471 (97·1%) patients at the time of hospital-
isation of which 217 (44·7%) were reported as consistent
with, 151 (31·1%) were indeterminate for and 103
(21·2%) inconsistent with COVID-19. Patients who were
considered appropriate for level three care were more
likely to have chest radiography consistent with COVID-
19 compared to those who were not (p < 0·001), suggest-
ing a higher severity of disease in these patients.
Treatments administered during hospitalisation
During hospitalisation, a total of 383 (79·0%) patients re-
quired oxygen therapy, 88 (18·1%) received CPAP, 38
(7·8%) received mechanical ventilation, renal
Table 1 Baseline clinical characteristics of patients divided by ceiling of care decisions
All patients (n = 409) Level 1 (n = 208) Level 2 (n = 75) Level 3(n = 126) p-value
Demographics
Age (years) 73·1 ± 15·3 81·9 ± 9·4 75·4 ± 9·9 57·6 ± 12·8 < 0·001
Male sex [n(%)] 211 (54) 103 (49·5) 43 (57·3) 75 (59·5) 0·17
BMI (kg/m2) 26·3 (22·1–30·8) 23·2 (20·5–27·1) 27·6 (22·0–31·8) 29·4 (25·8–34·0) < 0·001
BAME [n(%)] 56 (13·7) 12 (5·8) 8 (10·7) 36 (28·6) < 0·001
Clinical Frailty Scale 5 (3–6) 6 (5–7) 4 (3–5) 2 (2–3) < 0·001
Co-morbidities
HFrEF [n(%)] 51 (12·5) 34 (16·3) 13 (17·3) 4 (3·2) 0·001
IHD [n(%)] 62 (15·2) 39 (18·8) 15 (20·0) 8 (6·3) 0·004
Hypertension [n(%)] 191 (46·7) 99 (47·6) 44 (58·7) 48 (38·1) 0·017
AF [n(%)] 87 (21·3) 60 (28·8) 17 (22·7) 10 (7·9) < 0·001
Diabetes mellitus [n(%)] 125 (30·6) 67 (32·2) 32 (42·7) 26 (20·6) 0·004
Stroke/TIA [n(%)] 48 (11·7) 34 (16·3) 10 (13·3) 4 (3·2) 0·001
CKD [n(%)] 103 (25·2) 69 (33·2) 29 (38·7) 5 (4·0) < 0·001
COPD [n(%)] 64 (15·6) 41 (19·7) 16 (21·3) 7 (5·6) 0·001
Malignancy [n(%)] 33 (8·1) 22 (10·6) 7 (9·3) 4 (3·2) 0·050
Medications
ACEi [n(%)] 74 (18·1) 30 (14·4) 23 (30·7) 21 (16·7) 0·007
ARB [n(%)] 32 (7·8) 10 (4·8) 8 (10·7) 14 (11·1) 0·069
BB [n(%)] 99 (24·2) 61 (29·3) 22 (29·3) 16 (12·7) 0·001
CCB [n(%)] 68 (16·6) 27 (13·0) 20 (26·7) 21 (16·7) 0·024
Loop diuretic [n(%)] 64 (15·6) 50 (24·0) 12 (16·0) 2 (1·6) < 0·001
MRA [n(%)] 16 (3·9) 11 (5·3) 3 (4·0) 2 (1·6) 0·24
Statin [n(%)] 171 (41·8) 85 (40·4) 49 (65·3) 38 (30·2) < 0·001
Antiplatelet [n(%)] 105 (25·7) 57 (27·4) 23 (30·7) 25 (19·8) 0·17
Anticoagulant [n(%)] 57 (13·9) 42 (20·2) 11 (14·7) 4 (3·2) < 0·001
Metformin [n(%)] 50 (12·2) 23 (11·1) 14 (18·7) 13 (10·3) 0·17
Sulphonylurea [n(%)] 20 (4·9) 5 (2·4) 8 (10·7) 7 (5·6) 0·016
Corticosteroid [n(%)] 21 (5·1) 12 (5·8) 3 (4·0) 6 (4·8) 0·82
Immunosuppression [n(%)] 21 (5·1) 9 (4·3) 5 (6·7) 7 (5·6) 0·71
BMI body mass index, BAME Black Asian and minority ethnic, BMI body mass index, HFrEF heart failure with reduced ejection fraction, IHD ischaemic heart disease,
AF atrial fibrillation, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II
receptor blocker, BB beta-adrenoceptor antagonist, CCB calcium channel blocker, MRA mineralocorticoid receptor antagonist
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replacement therapy was used in 11 (2·3%) and 28 (5·8%)
patients required inotropes or vasopressors. CPAP was
delivered in a ward setting for 6 (6.8%), on the high-
dependency unit for 13 (14·8%) and on ICU for 69
(78·4%). All patients who required mechanical ventila-
tion were cared for in an ICU setting. Overall, 92
(19·0%) of patients were admitted to ICU, 61 (81·3%) of
whom were deemed suitable for level three care, whilst
14 (18·7%) were suitable for, and received, level two
care.
Clinical outcomes
At the time of censorship a total of 307 (63·3%) patients
had been discharged from hospital following a mean
hospital stay of 12·7 ± 10·5 days. Overall 159 (32·8%) pa-
tients died prior to discharge with a mean follow-up of
12·6 ± 11·2 days after admission, whilst 19 (3·9%)
remained in hospital. Despite on average having more
markers of disease severity, patients deemed to be
suitable for level three care were more likely to be
discharged and less likely to have died during hospital-
isation (p < 0·001) (Fig. 3). Of the 20 (16%) patients eli-
gible for level three care who died during the study
period, all were admitted to ICU and received mechan-
ical ventilation prior to death. Overall, including patients
in whom ceiling of care decisions were not documented,
38 (7·8%) received mechanical ventilation during the
study period and of these seven (18·4%) had been dis-
charged, nine (23·7%) remained in hospital and 22
(57·9%) had died.
Death during admission was associated with advanced
age, White-European ethnicity, higher CFS, a diagnosis
of HFrEF, atrial fibrillation, CKD or COPD and the pre-
scription of anticoagulant (Table 5). When adjusted for
age and sex, associations between death during admis-
sion and higher CFS remained (OR 1·2, 95% CI 1·1–1·4,
p = 0·001), but not the associations with White-
European ethnicity, any major co-morbidity or medica-
tion. In a multivariable model including age, CFS and
maximum level of care receiving during admission,
Fig. 1 Bar charts showing a age, b ethnicity, c Clinical Frailty Scale and d co-morbidities in patients deemed appropriate for level one, two or
three care. Patients in the present study were often elderly, frail and were multi-morbid
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receipt of level two (OR 2·6, 95% CI 1·1–11·6, p = 0·033)
or level three care (OR 8·1, 95% CI 3·7–17·8, p < 0·001)
were associated with an increased risk of death during
hospitalisation.
Discussion
In this study, we present data regarding pre-emptive
advanced care planning in patients admitted with SARS-
CoV-2 infection during the COVID-19 pandemic
according to national recommendations [17]. These
decisions were made for the majority of hospitalised
patients, who were often elderly, frail and multi-morbid.
Advanced age, higher CFS and the accrued number of
co-morbidities were independently associated with a de-
cision to limit the ceiling of care below full intensive
care-based treatment (level three). In contrast, only age
and frailty were associated with death during hospitalisa-
tion, suggesting studies using ICU admission as a pri-
mary endpoint and/or measure of disease severity might
be confounded by these decisions, which are infre-
quently available in care records.
Addressing goals of care during the COVID-19 pandemic
Early reports from Wuhan [10, 18, 19] and Lombardy
[2] highlighted the risks to patients due to demand for
ICU care surpassing surge capacity [20, 21].
















Odds of level 3 care
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OR 95% CI p-value
1 (ref)
0 11 (0 058-0 22) <0 001
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0 041 (0 018-0 096) <0 001
1 (ref)
0 15 (0 078-0 30) <0 001
0 009 (0 003-0 027) <0 001
0 007 (0 002-0 025) <0 001
Fig. 2 Forrest plot showing unadjusted odds ratios of appropriateness of level three care associated with demographic and clinical variables.
There were associations between treatment escalation decisions and age, frailty and burden of co-morbidities
Table 2 Multivariable binary regression analysis of clinical
characteristics and ceiling of care decisions (with individual co-
morbidities)
Odds ratio 95% CI p-value
Age (per year) 0·89 0·86–0·92 < 0·001
Male sex 1·8 0·81–4·0 0·15
CFS (per nodal point) 0·47 0·37–0·60 < 0·001
Diabetes 0·49 0·20–1·2 0·11
COPD 0·60 0·19–1·9 0·38
CKD 0·31 0·093–1·1 0·062
Stroke/TIA 1·1 0·25–5·1 0·88
Loop diuretic 0·27 0·031–2·3 0·23
Statin 0·68 0·30–1·5 0·35
CI confidence interval, CFS Clinical Frailty Scale, COPD chronic obstructive
pulmonary disease, CKD chronic kidney disease, TIA transient ischaemic attack
Table 3 Multivariable binary regression analysis of clinical
characteristics and ceiling of care decisions (with cumulative
number of co-morbidities)
Odds ratio 95% CI p-value
Age (per year) 0·89 0·86–0·93 < 0·001
Male sex 1·75 0·79–3·8 0·17
CFS (per nodal point) 0·48 0·38–0·60 < 0·001
Co-morbidities (per co-morbidity) 0·72 0·52–1·0 0·048
Loop diuretic 0·23 0·026–2·1 0·19
Statin 0·65 0·30–1·4 0·28
CI confidence interval, CFS Clinical Frailty Scale
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Considerable focus on preparedness has therefore in-
cluded timely and patient-centred pre-emptive discus-
sions, addressing advanced care planning in the setting
of a potentially fatal illness which disproportionately ef-
fects the elderly and those with underlying health condi-
tions. The priorities of such decisions were to avoid
intensive and distressing treatments in patients who
would not want to receive them and to manage patients
appropriately according to the likelihood of benefit from
intensive treatment [22].
Advanced care planning can be challenging for pa-
tients and healthcare professionals. It is essential that
such discussions occur at an appropriate time and are
framed within the individual patient’s beliefs and wishes
[23]. At LTHT, establishing and documenting goals of
care were assisted by the availability of the ReSPECT
process [15]. This simple electronic documentation is
standardised across care settings, and is recognised
regionally by hospitals, primary care practices and
ambulance services, and facilitates timely shared
decision-making amongst patients, their next-of-kin and
surrogate decision makers. Ceiling of care and CPR
resuscitation decisions were documented in a high pro-
portion of patients (84·3% and 93·0%) admitted with
SARS-CoV-2 infection. Hence, LTHT is well-placed to
report on the clinical application of this approach.
The COVID-19 pandemic continues to challenge
healthcare systems globally, and has raised important
ethical issues, particularly the need to prioritise access to
limited resources to those with the greatest chance of
survival and anticipated shorter recovery [20, 22]. The
majority of our patients were considered inappropriate
for escalation of care to an ICU setting, or for CPR. Al-
though this could imply that decisions were influenced
by a drive to protect resources, ICU and ward bed occu-
pancy at LTHT was below surge capacity throughout
the study period and a local database monitored and dis-
seminated this information to treating teams daily.
Hence, although a higher proportion of patients had the
ReSPECT process completed during the peak months of
the pandemic than would usually be expected, LTHT
did not experience a severe shortage of ICU bed
Table 4 Markers of severity of disease divided by ceiling of care decisions
All patients (n = 409) Level 1 (n = 208) Level 2 (n = 75) Level 3 (n = 126) p-value
Laboratory findings
Hb 129·2 ± 20·7 126·6 ± 21·8 125·0 ± 21·6 135·9 ± 16·5 < 0·001
WCC 7·0 (5·4–9·4) 7·2 (5·4–10·0) 6·5 (5·0–9·1) 7·1 (5·6–9·5) 0·23
ANC 5·4 (4·0–8·0) 5·7 (4·0–8·9) 5·1 (3·9–7·8) 5·6 (4·2–8·3) 0·38
Lymphocyte count 0·8 (0·5–1·1) 0·7 (0·5–1·1) 0·7 (0·5–1·0) 0·8 (0·6–1·1) 0·12
Na2+ 138 (136–141) 140 (136–145) 137 (135·8–140) 137 (135–139) < 0·001
K+ 4·0 (3·7–4·4) 4·0 (3·7–4·5) 4·2 (3·7–4·5) 3·9 (3·7–4·2) 0·034
Creatinine 81 (63–117) 95 (68–143) 86·5 (65·8–129·5) 74 (60·3–89·8) < 0·001
CRP 90 (45–169) 77·5 (34·8–159·8) 106 (72·3–187·3) 110 (68–192) 0·001
Ddimer 467 (258·5–1035·3) 496 (266–1978) 671 (387–1042) 373 (223–924) 0·068
hsTNI 20·5 (8·1–60) 40·0 (17·2–94·3) 25·5 (9·9–70·5) 8·5 (4·6–22·2) < 0·001
Ferritin 460 (220–982) 365 (143·8–671·5) 510 (261·3–946) 674 (338·5–1458) < 0·001
Procalcitonin 0·15 (0·08–0·38) 0·17 (0·08–0·52) 0·14 (0·08–0·32) 0·15 (0·09–0·40) 0·60
Clinical observations
RR (min−1) 22 (18–28) 20 (18–28) 22·5 (20–28) 24 (20–29) 0·026
O2 saturations (%) 94·5 (89–96) 95 (90–97) 94 (88–96) 94 (89–96) 0·065
Heart rate (min−1) 90 (76–103) 89 (73–102·8) 89 (79–101·3) 96 (86–108·5) 0·001
SBP (mmHg) 129·2 ± 23·5 130·4 ± 25·5 131·2 ± 24·4 126·2 ± 18·8 0·21
Temperature (°C) 37·7 ± 1·1 37·4 ± 1·1 37·7 ± 1·1 38·0 ± 1·0 < 0·001
Chest radiography
COVID-19 [n(%)] 190 (47·4) 61 (29·6) 40 (55·6) 89 (72·4) < 0·001
Indeterminate [n(%)] 125 (31·2) 79 (38·2) 22 (30·6) 24 (19·5)
Non-COVID-19 [n(%)] 86 (21·4) 66 (32·0) 10 (13·9) 10 (8·1)
Hb haemoglobin, WCC white cell count, ANC absolute neutrophil count, Na2+ sodium, K+ potassium, CRP C-reactive protein, hsTNI high-sensitivity troponin-I, RR
respiratory rate, O2 oxygen, SBP systolic blood pressure
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capacity, making it unlikely that the outcomes of these
assessments were biased towards a particular decision by
the capacity to provide care. The high rate of not-for-
resuscitation and ceiling of care decisions therefore
probably reflects the demographics and clinical charac-
teristics of our patients who were often elderly, frail and
multi-morbid. Furthermore, in a multivariable model ad-
justed for age and CFS, receipt of level two or three care
were associated with an increased risk of death, reflect-
ing baseline differences in disease severity in patients
who were considered appropriate for intensive treat-
ments. It is feasible, however, that a more challenging
environment including the requirement for appropriate
personal protective equipment prior to CPR, risks of
transmission to healthcare professionals [24] and the
limited effectiveness of cardiopulmonary resuscitation in
the setting of COVID-19 [25] may have influenced these
decisions.
Demographic and clinical characteristics and their
association with ceiling of care decisions
In response to the appreciation that a high proportion of
patients admitted with SARS-CoV-2 infection were eld-
erly and frail, and therefore potentially unlikely to bene-
fit from intensive treatments, even in the absence of
COVID-19 infection, on 20th March 2020 the National
Institute for Health and Care Excellence (NICE) pro-
duced guidance that included the CFS as an adjunct to
assist in discussions with patients and carers around
advanced care planning and suitability for ICU care in
the event of deterioration [17]. The CSF is a nine point
scale which provides healthcare professionals with a sim-
ple screening tool for measuring frailty. The CSF has
been validated in frail patients receiving ICU care, in
which it reliably predicts outcomes [26, 27]. In our pa-
tients, frailty was a strong predictor of ceiling of care de-
cisions, which is likely to reflect both the known poor
prognosis in frail patients receiving ICU and also the
aforementioned national recommendations. As would be
expected, advanced age was strongly associated with
these decisions, with patients aged over 85 years being
far more likely to be deemed ineligible for level three
care compared to those under 65.
BAME patients were more likely than White-European
patients to be considered appropriate for level three care
(OR 5·7, 95% CI 3·1–10·4, p < 0·001), however they were
on average younger, had fewer co-morbidities and were
less frail. In age-sex adjusted analysis, ethnicity was not
associated with ceiling of care suggesting that these deci-
sions are unlikely to be contributing to the worse out-
comes in BAME patients. These observations are
relevant to observational data from the UK and else-
where with White-European patients being on average
older.
ICU admission per se is not a reliable marker of severe
disease when advanced care planning is routine
The low rate of public testing for SARS-CoV-2 infection
in many countries meant that studies have often been
limited to hospitalised patients which have not consid-
ered the confounding effects of advanced care planning,
such that a valid picture of risk factors for severe disease
in elderly, frail and multi-morbid populations is un-
known. Studies investigating risk factors in COVID-19
have often classified ICU admission as a marker of se-
vere disease, either in recognition of poor outcomes in
these patients or where mortality data were not yet avail-
able. For example, a population based study in the UK
found that the receipt of an angiotensin-converting en-
zyme inhibitor (ACEi) or angiotensin-II-receptor blocker
(ARB) were associated with a reduced risk (except in
Black-African patients) of severe disease [9]. However,
without accounting for the confounding effects of these
decisions, admission to ICU or receipt of mechanical
ventilation might be associated with better prognosis
when compared with conservative management for
patients in whom these treatments were considered in-
appropriate or futile [28]. Furthermore, these observa-
tions have not been confirmed in studies restricted to
patients already on ICU in which death was the primary
end-point [29, 30].
In our patients, prescription of ACEi (but not ARB)












Fig. 3 Bar charts showing outcomes of patients appropriate for level
one, two or three care. Patients appropriate for level three care were
the most likely to be discharged and least likely to have died during
admission. p-value < 0·05*, < 0·01**, < 0·001***
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considered appropriate for level three care, but was not
associated with an increased risk of death during hospi-
talisation. These observations may be a result of biases
introduced by pre-emptive ceiling of care decisions
where those with co-morbidities are not considered for
ICU care, and the relative risk of severe disease therefore
appears less where this definition is applied. In our
patients, admission to ICU was guided by these pre-
emptive decisions in addition to severity of disease,
however, the setting of care was not consistent for all
patients. For example, some patients who were deemed
inappropriate for mechanical ventilation received CPAP
in an ICU setting, whilst others received these treat-
ments in a ward or high-dependency unit.
A further paradox revealed by our data is that whilst
patients deemed appropriate for level three care were
more unwell at presentation, as evidenced by more ab-
normal laboratory values, chest radiography and physio-
logical assessment, when compared to patients suitable
for level one or two care, outcomes were favourable with
the vast majority surviving until discharge. In our ana-
lysis, all those patients deemed appropriate for level
three care who then died, did so following escalation of
their care to an ICU setting and mechanical ventilation.
Table 5 Baseline clinical characteristics of patients divided by those who were alive or had died during the study period
All patients (n = 485) Alive (n = 326) Dead (n = 159) p-value
Demographics
Age (years) 71·6 ± 16·3 68·4 ± 17·4 78·1 ± 11·5 < 0·001
Male sex [n(%)] 259 (53·4) 168 (51·5) 91 (57·3) 0·24
BMI (kg/m2) 26·3 (22·1–30·8) 26·7 (22·2–31·4) 25·5 (21·9–29·9) 0·13
BAME [n(%)] 73 (15·4) 59 (18·6) 14 (8·9) 0·006
Clinical Frailty Scale 5 (3–6) 3 (2–6) 6 (3–7) < 0·001
Co-morbidities
HFrEF [n(%)] 59 (12·2) 31 (9·5) 28 (17·6) 0·010
IHD [n(%)] 69 (14·2) 46 (14·1) 23 (14·5) 0·92
Hypertension [n(%)] 222 (45·8) 155 (47·5) 67 (42·1) 0·26
AF [n(%)] 97 (20·0) 52 (16·0) 45 (28·3) 0·001
Diabetes mellitus [n(%)] 147 (30·3) 90 (27·6) 57 (35·8) 0·064
Stroke/TIA [n(%)] 53 (10·9) 32 (9·8) 21 (13·2) 0·26
CKD [n(%)] 119 (24·5) 71 (21·8) 48 (30·2) 0·043
COPD [n(%)] 69 (14·2) 37 (11·3) 32 (20·1) 0·009
Malignancy [n(%)] 37 (7·6) 23 (7·1) 14 (8·8) 0·50
Medications
ACEi [n(%)] 84 (17·3) 57 (17·5) 27 (17·0) 0·89
ARB [n(%)] 41 (8·5) 31 (9·5) 10 (6·3) 0·23
BB [n(%)] 113 (23·3) 75 (23·0) 38 (23·9) 0·83
CCB [n(%)] 80 (16·5) 57 (17·5) 23 (14·5) 0·40
Loop diuretic [n(%)] 74 (15·3) 47 (14·4) 27 (17·0) 0·46
MRA [n(%)] 18 (3·7) 12 (3·7) 6 (3·8) 0·96
Statin [n(%)] 200 (41·2) 136 (41·7) 64 (40·3) 0·76
Antiplatelet [n(%)] 115 (23·7) 75 (23·0) 40 (25·2) 0·60
Anticoagulant [n(%)] 67 (13·8) 38 (11·7) 29 (18·2) 0·049
Metformin [n(%)] 61 (12·6) 39 (12·0) 22 (13·8) 0·56
Sulphonylurea [n(%)] 23 (4·7) 18 (5·7) 5 (3·2) 0·23
Corticosteroid [n(%)] 24 (4·9) 14 (4·3) 10 (6·4) 0·34
Immunosuppression [n(%)] 22 (4·5) 13 (4·0) 9 (5·7) 0·41
BMI body mass index, BAME Black Asian and minority ethnic, BMI body mass index, HFrEF heart failure with reduced ejection fraction, IHD ischaemic heart disease,
AF atrial fibrillation, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II
receptor blocker, BB beta-adrenoceptor antagonist, CCB calcium channel blocker, MRA mineralocorticoid receptor antagonist
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Overall 14 (18·7%) of patients deemed eligible for level
two and 61 (48·8%) of those deemed eligible for level
three care were admitted to an ICU setting allowing for
delivery of key treatments for COVID-19 of CPAP and
mechanical ventilation. Including patients in whom ceil-
ing of care decisions were not made, 38 (7·8%) patients
received mechanical ventilation. This rate was low com-
pared to earlier reports from Wuhan and Lombardy, but
similar to contemporary reports from the UK [7]. Des-
pite an average age of 57·8 ± 13·2 years, more than half
of these patients had died at follow-up, with fewer than
one in five having a successful discharge and, at the time
of reporting, almost a quarter still in hospital. It might
therefore be reasonable to regard mechanical ventilation
as a marker of severe disease in patients who remain in
hospital at the time of censorship, due to the poor prog-
nosis in this group.
Strengths and limitations
This is an analysis of a carefully characterised cohort of
consecutively admitted patients with SARS-2-CoV infec-
tion in whom standardised documentation of ceiling of
care decisions was routine and completed in the major-
ity of cases. The principle limitations are inherent to the
retrospective design and single centre setting, and our
findings should be interpreted in light of this. Recom-
mendations to assist treating teams making ceiling of
care decisions were available [17], however these have
not been validated in COVID-19, nor are there rando-
mised data supporting their use. These decisions were
not standardised, rather they were made between pa-
tients, their next-of-kin or surrogate decision makers fol-
lowing discussions regarding their goals of care. Whilst
we recognise that there is a risk of undertreatment with
this approach, it is also the case that undertreatment
from a medical perspective may not equate to under-
treatment from the perspective of patients or their
relatives.
In our manuscript we show that individual co-
morbidities were not associated with decisions to limit
care, however accrued co-morbidities were. The inclu-
sion of a validated co-morbidity index may have
enriched our analysis of the impact of co-morbidities on
ceiling of care decisions. An additional limitation is the
low proportion of patients in this study who were
BAME, although the proportion is in line with census
data and representative of local demographics. BAME
patients were younger and had fewer co-morbidities
than White European patients making definitive conclu-
sions regarding the impact of ethnicity on advanced care
planning difficult. The availability of ICU beds [31],
demographic and cultural differences between countries
may limit the generalisability of our findings. The need
for oxygen therapy is an imprecise outcome reflecting a
wide range of disease severities, however is in line with
other observational and interventional studies in
COVID-19 [32]. Finally, the follow-up time is relatively
short and outcomes data were therefore not available for
patients who remained in hospital.
Conclusions
To our knowledge, this study is the first to report ceiling
of care and CPR decisions during the COVID-19 pan-
demic and their association with demographic and clin-
ical characteristics. Decisions were made broadly in line
with known predictors of poor outcomes in COVID-19,
but with a focus on co-morbidities suggesting ICU ad-
mission might not a reliable endpoint for observational
datasets aiming to explore risk factors of severe disease,
with those at the greatest risk of death being the least
likely to receive intensive treatments.
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